ArticleKidney international2021
Bortezomib plus dexamethasone for rituximab-resistant PLA2R
Article in Kidney international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Research Advances in Rituximab-Resistant Membranous Nephropathy.Kidney medicine · 2026Review
- Article
- Treatment strategies for rituximab-resistant primary membranous nephropathy: from resistance mechanisms to emerging therapies.Frontiers in immunology · 2026Review
- Response To the Letter to the Editor Entitled "First Report of Daratumumab Therapy in Refractory THSD7A-Positive Membranous Nephropathy".Kidney international reports · 2025Article
- Plasma Cell-Directed Rescue With Bortezomib in Refractory Antiphospholipase A2 Receptor-Positive Membranous Nephropathy.Kidney international reports · 2025Article
- Prospective Pilot Study of Plasma Cell-Targeted Therapy With Bortezomib in Refractory IgA Nephropathy.Kidney international reports · 2025Article
- Newer B-cell and plasma-cell targeted treatments for rituximab-resistant patients with membranous nephropathy.Clinical kidney journal · 2025Review
- Impact of immune cell metabolism on membranous nephropathy and prospective therapy.Communications biology · 2025Review
- Therapeutic targets in membranous nephropathy: plasma cells and complement.Clinical kidney journal · 2024Review
- Infectious Disease Prophylaxis During and After Immunosuppressive Therapy.Kidney international reports · 2024Review
- Membranous nephropathy: pathogenesis and treatments.MedComm · 2024Review
- Ten tips on immunosuppression in primary membranous nephropathy.Clinical kidney journal · 2024Review
- Clinical advances in immunotherapy for immune-mediated glomerular diseases.Clinical and experimental medicine · 2023Review
- How to Choose the Right Treatment for Membranous Nephropathy.Medicina (Kaunas, Lithuania) · 2023Review
- Future landscape for the management of membranous nephropathy.Clinical kidney journal · 2023Review
- Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy.Drugs · 2023Review
- Novel Treatments Paradigms: Membranous Nephropathy.Kidney international reports · 2023Review
- Primary membranous nephropathy: an endless story.Journal of nephrology · 2023Review
- Case report: Successful treatment of refractory membranous nephropathy with telitacicept.Frontiers in immunology · 2023Article
- Review
Corrections and comments
- Commented on by
- Comment on
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.